Synopsys (SNPS) shares closed more than 4% higher on Thursday, July 3 following the White House’s decision to lift ...

A large-scale Mendelian randomization study found no genetic evidence that vitamins A, C, or D reduce the risk of major ...

In the latest trading session, Synopsys (SNPS) closed at $536.52, marking a -2.23% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.79%. Elsewhere, the Dow ...

Human genotyping has never been hotter, and a sophisticated set of array-based tools now simplifies the process dramatically, facilitating everything from small basic research studies to complex ...

Synopsys is set for a faster rebound due to China sales resuming, an $8B backlog, and strong AI-driven tool demand. Click ...

With the recent completion of the Perlegen–US National Institute of Environmental Health Sciences mouse resequencing project 1, which adds 8 million single nucleotide polymorphisms (SNPs) to the ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

Synopsys shares gained after the White House lifted restrictions on export of chip-design software to China. Berenberg analysts believe SNPS shares could hit $600 in the coming months. Synopsys ...

State Medicaid agencies can improve D-SNP financial transparency and reward those D-SNPs that provide the best value to states, the federal government, and taxpayers through strategic use of D-SNP ...